Sirolimus Eluting Stents
نویسندگان
چکیده
منابع مشابه
Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents
BACKGROUND The biodegradable polymer drug-eluting stents (DES) were developed to improve vascular healing. However, further data and longer-term follow-up are needed to confirm safety and efficacy of these stents. This randomized clinical trial aimed to compare safety and efficacy of 2 sirolimus-eluting stents (SES): Cordimax-a novel abluminal biodegradable polymer SES and Cypher Select-a durab...
متن کاملSirolimus-eluting coronary stents: a review
The sirolimus-eluting coronary stent received CE Mark approval in Europe in April 2002. In the US, FDA approval followed in April 2003. Since the preliminary results from the First-in-Man feasibility study were presented, several randomized, controlled trials have documented the profound antiproliferative effects of sirolimus, a macrolide antibiotic and potent cytostatic inhibitor of smooth mus...
متن کاملEconomic evaluation of sirolimus-eluting stents.
BACKGROUND Sirolimus-eluting stents have recently been shown to reduce the risk of restenosis among patients who undergo percutaneous coronary intervention (PCI). Given that sirolimus-eluting stents cost about 4 times as much as conventional stents, and considering the volume of PCI procedures, the decision to use sirolimus-eluting stents has large economic implications. METHODS We performed ...
متن کاملPaclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus
Background—Diabetes is a powerful predictor of adverse events in patients undergoing percutaneous coronary intervention. Drug-eluting stents reduce restenosis rates compared with bare metal stents; however, controversy remains regarding which drug-eluting stents provides greater benefit in patients with diabetes. Accordingly, we compared the safety and efficacy of sirolimus-eluting stents (SES)...
متن کاملEconomics of sirolimus-eluting stents: drug-eluting stents have really arrived.
Since the development of coronary angioplasty in the late 1970s, there have been a series of technical advancements that have improved the outcome of the procedure. Clearly, the biggest advance was to move from balloon angioplasty to intracoronary stenting and now to drug-eluting stents (DES).1,2 These advances have been shown to reduce in-hospital events and to dramatically lower the incidence...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Medicine Insights: Therapeutics
سال: 2010
ISSN: 1179-559X,1179-559X
DOI: 10.4137/cmt.s2094